** Shares of drugmaker Ionis Pharmaceuticals IONS.O rise ~8% to $38.43 premarket
** On Thursday, IONS said the U.S. FDA approved co's genetic disorder drug, olezarsen, to treat familial chylomicronemia syndrome (FCS)
** FCS is a condition that prevents the body from breaking down fats and is characterized by extremely high levels of triglycerides
** Brokerage TD Cowen forecasts peak sales of $82 mln in FY32 for FCS market
** 17 of 25 brokerages rate the stock "buy" or higher, 7 "hold" and 1 "sell"; their median PT is $62 - LSEG
** As of last close, stock has fallen 29.7% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。